Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Nanobiotix spins out Curadigm

"While Nanobiotix remains focused on development of NBTXR3, Curadigm will open new growth pathways for Nanobiotix beyond...

Genetically modified fungus stops malaria mosquitoes

In field trials in Burkina Faso, US researchers infected the mosquitoes with spores of the poisonous fungus Metarhizium pingshaense. Within six...

Healthy figures from Spain

The early data suggests that 2018 was a year of historically high specialised investment in biotechnology. More than €94m of private capital were...

Swedish researchers find new pain organ

Almost one person in every five experiences constant pain and there is a considerable need to find new painkilling drugs. However, sensitivity to...

Biophytis launches €9m Nasdaq IPO

The clinical-stage biotech company based in Paris filed a registration statement to offer 13,125,000 of its ordinary shares in a global offering,...

Researchers find clue to Parkinson's gene therapy

The scientists headed by Juan Gerez and Paola Picotti identified a biochemical process in mice models that breaks down the accumulation of proteins...

€8m for universal flu vaccine

One vaccine to prevent all flu infections now and in future: with this premise, French vaccine maker Osivax has managed to secure €8m in a Series A...